BridgeBio Pharma Inc (BBIO)
30.10
-0.94
(-3.04%)
USD |
NASDAQ |
May 17, 16:00
30.10
0.00 (0.00%)
After-Hours: 20:00
BridgeBio Pharma Revenue (Quarterly): 211.12M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 211.12M |
| December 31, 2023 | 1.745M |
| September 30, 2023 | 4.091M |
| June 30, 2023 | 1.641M |
| March 31, 2023 | 1.826M |
| December 31, 2022 | 1.87M |
| September 30, 2022 | 0.338M |
| June 30, 2022 | 73.75M |
| March 31, 2022 | 1.694M |
| December 31, 2021 | 12.89M |
| Date | Value |
|---|---|
| September 30, 2021 | 2.344M |
| June 30, 2021 | 54.02M |
| March 31, 2021 | 0.462M |
| December 31, 2020 | 0.122M |
| September 30, 2020 | 8.127M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 13.82M |
| September 30, 2019 | 26.74M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.122M
Minimum
Dec 2020
211.12M
Maximum
Mar 2024
24.51M
Average
2.344M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Pfizer Inc | 14.88B |
| Alnylam Pharmaceuticals Inc | 494.33M |
| Regenxbio Inc | 15.62M |
| ACADIA Pharmaceuticals Inc | 205.83M |
| Biomarin Pharmaceutical Inc | 648.83M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -35.22M |
| Total Expenses (Quarterly) | 207.38M |
| EPS Diluted (Quarterly) | -0.20 |
| Enterprise Value | 6.840B |
| Gross Profit Margin (Quarterly) | 99.72% |
| Profit Margin (Quarterly) | -16.68% |
| Earnings Yield | -10.70% |
| Normalized Earnings Yield | -10.38 |